1. Home
  2. MARPS vs CALC Comparison

MARPS vs CALC Comparison

Compare MARPS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marine Petroleum Trust Units of Beneficial Interest

MARPS

Marine Petroleum Trust Units of Beneficial Interest

HOLD

Current Price

$4.31

Market Cap

8.9M

Sector

Energy

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$1.08

Market Cap

7.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MARPS
CALC
Founded
1956
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.9M
7.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MARPS
CALC
Price
$4.31
$1.08
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $38.00
AVG Volume (30 Days)
4.6K
★ 56.0K
Earning Date
11-13-2026
11-11-2026
Dividend Yield
★ 7.21%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.39
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.05
$0.44
52 Week High
$6.49
$72.00

Technical Indicators

Market Signals
Indicator
MARPS
CALC
Relative Strength Index (RSI) 48.54 23.53
Support Level $4.24 $0.44
Resistance Level $4.90 $2.31
Average True Range (ATR) 0.10 0.12
MACD 0.03 0.05
Stochastic Oscillator 61.62 0.00

Price Performance

Historical Comparison
MARPS
CALC

About MARPS Marine Petroleum Trust Units of Beneficial Interest

Marine Petroleum Trust is a U.S .-based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of America. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: